[go: up one dir, main page]

MX2018006343A - Composicion farmaceutica que contiene 2-{4-[n-(5,6-difenilpirazin- 2-il)-n-isopropilamino]butiloxi}-n-(metilsulfonil)acetamida. - Google Patents

Composicion farmaceutica que contiene 2-{4-[n-(5,6-difenilpirazin- 2-il)-n-isopropilamino]butiloxi}-n-(metilsulfonil)acetamida.

Info

Publication number
MX2018006343A
MX2018006343A MX2018006343A MX2018006343A MX2018006343A MX 2018006343 A MX2018006343 A MX 2018006343A MX 2018006343 A MX2018006343 A MX 2018006343A MX 2018006343 A MX2018006343 A MX 2018006343A MX 2018006343 A MX2018006343 A MX 2018006343A
Authority
MX
Mexico
Prior art keywords
diphenylpyrazin
butyloxy
isopropylamino
acetamide
methylsulfonyl
Prior art date
Application number
MX2018006343A
Other languages
English (en)
Other versions
MX385595B (es
Inventor
Furuta Shoji
Mukai Hironori
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59014064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018006343(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of MX2018006343A publication Critical patent/MX2018006343A/es
Publication of MX385595B publication Critical patent/MX385595B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona una preparación sólida estabilizada de la 2-{4-[N-(5,6-difenilpirazin-2-il)-N-isopropilamino]butiloxi}-N-(m etilsulfonil)acetamida. Una preparación sólida que contiene la 2-{4-[N-(5,6-difenilpirazin-2-il)-N-isopropilamino]butiloxi}-N-(m etilsulfonil)acetamida y el D-manitol que tiene un área superficial específica de 1.0 m2/g o menor.
MX2018006343A 2015-12-02 2016-12-01 Composicion farmaceutica que contiene 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isopropilamino]butiloxi}-n-(metilsulfonil)acetamida. MX385595B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015236034 2015-12-02
PCT/JP2016/085822 WO2017098998A1 (ja) 2015-12-02 2016-12-01 ２－｛４－［ｎ－（５，６－ジフェニルピラジン－２－イル）－ｎ－イソプロピルアミノ］ブチルオキシ｝－ｎ－（メチルスルホニル）アセトアミドを含有する医薬組成物

Publications (2)

Publication Number Publication Date
MX2018006343A true MX2018006343A (es) 2018-08-01
MX385595B MX385595B (es) 2025-03-18

Family

ID=59014064

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006343A MX385595B (es) 2015-12-02 2016-12-01 Composicion farmaceutica que contiene 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isopropilamino]butiloxi}-n-(metilsulfonil)acetamida.

Country Status (32)

Country Link
US (2) US10821108B2 (es)
EP (3) EP4501404A3 (es)
JP (1) JP6825574B2 (es)
KR (1) KR102759845B1 (es)
CN (1) CN108289890B (es)
AU (1) AU2016366073B2 (es)
BR (1) BR112018009534B1 (es)
CL (1) CL2018001464A1 (es)
CO (1) CO2018006834A2 (es)
DK (1) DK4331607T3 (es)
EC (1) ECSP18049108A (es)
ES (1) ES3030325T3 (es)
FI (1) FI4331607T3 (es)
HR (1) HRP20250572T1 (es)
HU (1) HUE071411T2 (es)
IL (2) IL310203A (es)
LT (1) LT4331607T (es)
MX (1) MX385595B (es)
MY (1) MY198164A (es)
PE (1) PE20181072A1 (es)
PH (1) PH12018501161B1 (es)
PL (1) PL4331607T3 (es)
PT (1) PT4331607T (es)
RS (1) RS66791B1 (es)
RU (1) RU2735547C2 (es)
SA (1) SA518391686B1 (es)
SG (1) SG11201804320QA (es)
SI (1) SI4331607T1 (es)
TW (1) TWI750143B (es)
UA (1) UA124002C2 (es)
WO (1) WO2017098998A1 (es)
ZA (1) ZA201804387B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190204A1 (ar) 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
TW201922230A (zh) 2017-11-16 2019-06-16 日商日本新藥股份有限公司 控釋製劑
JP7430629B2 (ja) * 2018-02-21 2024-02-13 日本新薬株式会社 粒状組成物、粒状組成物の製造方法、および粒状組成物の溶出性改善方法
WO2020157730A1 (en) 2019-02-03 2020-08-06 Patel Jayendrakumar Dasharathlal A controlled release pharmaceutical composition of selexipag or it's active metabolite
US20210069187A1 (en) * 2019-05-11 2021-03-11 RK Pharma Solutions LLC Stable pharmaceutical composition of Selexipag
PE20221455A1 (es) * 2019-10-23 2022-09-21 Actelion Pharmaceuticals Ltd Composicion farmaceutica que comprende selexipag
JP7628504B2 (ja) 2019-11-25 2025-02-10 エセックス・ソリューションズ・ジャパン株式会社 絶縁電線、コイル、及び電気・電子機器
WO2021206159A1 (ja) * 2020-04-10 2021-10-14 日本新薬株式会社 固形製剤及びその製造方法
CN112220770B (zh) * 2020-12-17 2021-04-09 上海翰森生物医药科技有限公司 司来帕格的药物组合物及其制备方法
WO2022240378A1 (en) * 2021-05-11 2022-11-17 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi A stable pharmaceutical composition comprising selexipag

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3145431B2 (ja) 1991-08-20 2001-03-12 日本酸素株式会社 安定同位体標識蛋白質の製造法および試薬キット
JP3126683B2 (ja) 1996-04-16 2001-01-22 武田薬品工業株式会社 Ｄ−マンニトールおよびその製造法
US20010001106A1 (en) 1996-04-16 2001-05-10 Tomohiro Yoshinari D-mannitol and its preparation
WO2001089520A2 (en) 2000-05-19 2001-11-29 Progenics Pharmaceuticals, Inc. Dehydroascorbic acid formulations and uses thereof
EP1178047B1 (en) 2000-08-03 2004-02-25 Pfizer Products Inc. Diazabicyclooctane derivatives and therapeutic uses thereof
TWI316055B (es) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
US7112393B2 (en) 2003-07-29 2006-09-26 Canon Kabushiki Kaisha Non-magnetic toner
FR2918566B1 (fr) * 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
HRP20201352T1 (hr) 2008-02-28 2020-11-27 Nippon Shinyaku Co., Ltd. Inhibitor fibroze
WO2009154246A1 (ja) 2008-06-19 2009-12-23 日本新薬株式会社 勃起不全治療剤
ES2557303T3 (es) 2008-06-23 2016-01-25 Nippon Shinyaku Co., Ltd. Agente terapéutico para la estenosis del canal espinal
WO2009157397A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
PT2289518T (pt) 2008-06-23 2016-11-18 Nippon Shinyaku Co Ltd Agente terapêutico para doenças inflamatórias intestinais
TWI531565B (zh) * 2009-06-26 2016-05-01 艾克泰聯製藥有限公司 結晶體
EP2913047B1 (en) 2012-10-29 2019-05-08 Cardio Incorporated Pulmonary disease-specific therapeutic agent
CN103690496B (zh) 2013-12-27 2015-04-01 哈药集团生物工程有限公司 一种含有奥扎格雷钠的冻干药物组合物

Also Published As

Publication number Publication date
RU2018123304A (ru) 2020-01-09
US20180325895A1 (en) 2018-11-15
EP4331607B1 (en) 2025-04-30
PE20181072A1 (es) 2018-07-04
ECSP18049108A (es) 2018-10-31
IL259461A (en) 2018-07-31
JPWO2017098998A1 (ja) 2018-09-20
PT4331607T (pt) 2025-05-22
RU2735547C2 (ru) 2020-11-03
EP3384911A4 (en) 2019-05-15
CA3005169A1 (en) 2017-06-15
UA124002C2 (uk) 2021-07-07
SI4331607T1 (sl) 2025-06-30
SG11201804320QA (en) 2018-06-28
BR112018009534B1 (pt) 2023-11-07
CN108289890A (zh) 2018-07-17
EP4501404A3 (en) 2025-05-07
NZ742784A (en) 2024-08-30
EP4331607A3 (en) 2024-05-29
US10828298B2 (en) 2020-11-10
PH12018501161A1 (en) 2019-01-21
IL310203A (en) 2024-03-01
MY198164A (en) 2023-08-08
TW201720444A (zh) 2017-06-16
TWI750143B (zh) 2021-12-21
EP4501404A2 (en) 2025-02-05
AU2016366073B2 (en) 2021-08-26
US20180333413A1 (en) 2018-11-22
HRP20250572T1 (hr) 2025-07-04
FI4331607T3 (fi) 2025-06-03
SA518391686B1 (ar) 2024-03-03
DK4331607T3 (da) 2025-05-19
CO2018006834A2 (es) 2018-07-10
AU2016366073A1 (en) 2018-06-14
ES3030325T3 (en) 2025-06-27
LT4331607T (lt) 2025-06-10
WO2017098998A1 (ja) 2017-06-15
PH12018501161B1 (en) 2024-07-03
PL4331607T3 (pl) 2025-06-16
BR112018009534A2 (pt) 2018-11-06
KR20180081141A (ko) 2018-07-13
KR102759845B1 (ko) 2025-01-23
EP3384911A1 (en) 2018-10-10
RS66791B1 (sr) 2025-06-30
MX385595B (es) 2025-03-18
JP6825574B2 (ja) 2021-02-03
CL2018001464A1 (es) 2018-10-19
RU2018123304A3 (es) 2020-04-02
HUE071411T2 (hu) 2025-08-28
US10821108B2 (en) 2020-11-03
CN108289890B (zh) 2021-04-27
ZA201804387B (en) 2020-12-23
EP4331607A2 (en) 2024-03-06

Similar Documents

Publication Publication Date Title
ECSP18049108A (es) Composición farmacéutica que contiene 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isopropilamino]butiloxi}-n-(metilsulfonil)acetamida
CL2020003257A1 (es) Compuestos antagonistas de pcsk9.
ECSP18082774A (es) Derivados aromáticos de sulfonamida
CL2016002169A1 (es) Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados.
CL2015003298A1 (es) Novedosas heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
CL2016001889A1 (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1.
UY36275A (es) Compuestos aminopirimidinilo
MX2017002954A (es) Formas solidas cristialinas de 6-carboxi-2-(3,5-diclorofenil)-benz oxazol.
MX2020011478A (es) Formas solidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il) -1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida y sus composiciones farmaceuticas y usos.
CL2018000688A1 (es) Compuestos heterociclicos que contienen bencilamina y composiciones útiles contra infección por micobacterias
MX389026B (es) Una composicion farmaceutica y el uso de la misma.
EP3687475A4 (en) STABILIZATION OF EPINEPHRIN FORMULATIONS
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
CL2018002933A1 (es) Producto para el cuidado bucal.
EP3795166A4 (en) PHARMACEUTICAL COMPOSITION OF KOR RECEPTOR AGONIST
BR112016021902A2 (pt) Método de para estabilizar um substrato agregado tendo pelo menos uma superfície superior
EP3868383C0 (en) PHARMACEUTICAL USE OF ANEMOSIDE B4 IN ACUTE GOUTOUS ARTHRITIS
CL2017003383A1 (es) Procedimiento para la producción de urea sólida por granulación.
MX374540B (es) Desmopresina estabilizada.
UY36350A (es) Compuesto derivado de pirazol para tratamiento o prevención de la enfermedad de chagas.
BR112018074162A2 (pt) composições farmacêuticas adequadas para administração oral e administração parenteral, métodos para prevenir ou tratar infecção fúngica em um indivíduo humano ou animal e para produzir uma composição farmacêutica, e, uso de uma composição farmacêutica.
CU20160018A7 (es) Composiciones farmacéuticas de compuestos que inhiben la actividadde tirosina cinasa y sus métodos de preparación
AR109374A1 (es) Composición para el tratamiento de superficies duras
UA115290U (xx) Композиція у формі спрею для орального застосування, що містить холіну альфосцерат
UA118032U (uk) Фармацевтична композиція